ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO713

Prevalence of Diagnosed Polycystic Kidney Disease by Race/Ethnicity Among a Large Diverse United States Population, 1998-2018

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Aung, Thet T., Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
  • Chen, Qiaoling, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
  • Malik, Fatima T., Kaiser Permanente Los Angeles, Los Angeles, California, United States
  • Reynolds, Kristi, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
  • Jacobsen, Steven J., Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
  • Sim, John J., Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Background

While polycystic kidney disease (PKD) is considered a rare disease, it accounts for the 4th most common cause of ESRD in the United States (US). Estimates of PKD prevalence in Europe and the US are similar (30-50 per 100,000 persons) but whether differences exist across race/ethnicities is relatively unknown. We examined trends in the prevalence of diagnosed PKD overall and by race/ethnicity in a large, diverse healthcare delivery system with over 4.6 million members in the US.

Methods

Diagnosed PKD was identified among members aged ≥15 years in each calendar year from 1998 through 2018. PKD was defined as ≥2 separate encounter diagnoses for PKD (ICD9 codes 753.12, 753.13, 753.14, and ICD10 code Q61.2, Q61.19, Q61.3). Race/ethnicity was determined by self-report. Temporal trends in diagnosed PKD was examined overall and by race/ethnicity.

Results

A total of 7,580,947 members were included in the study period. Between 1998 and 2018, 3,524 members were identified as PKD with an overall prevalence of 46.5 cases per 100,000 people. The mean age of the PKD population was 49 years and comprised of 50% females with 10% Asians, 13% Blacks, 20% Hispanics, and 43% Whites. Prevalence (per 100,000) by race/ethnicity was 58.7, 84.5, 47.7, and 71.7 among Asians, blacks, Hispanics, and whites, respectively (p<0.001). Diagnosed prevalence of PKD increased among all racial/ethnic groups over the 20-years (Figure).

Conclusion

These data demonstrate sizeable differences in PKD prevalence by race/ethnicity. This information can help tailor strategies for identifying and managing this important population, based on the underlying population. Moreover, these data point to the potential to generate additional insights on the natural history/clinical course of this potentially modifiable genetic kidney disease.